Think of oxalate when using ascorbate supplementation to optimize iron therapy in dialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1463-1464

  Canavese, Caterina ^a   Marangella, Martino ^b   Stratta, Piero ^a  

^a Nephrology and Transplantation   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CALCIUM OXALATE; ERYTHROPOIETIN; IRON; OXALIC ACID; IRON DERIVATIVE; VITAMIN;

BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON KINETICS; IRON THERAPY; KIDNEY CLEARANCE; LETTER; PATIENT CARE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; UREMIA; VITAMIN SUPPLEMENTATION; ANEMIA; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; HYPEROXALURIA; NOTE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ANEMIA; ASCORBIC ACID; CALCIUM OXALATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; HUMANS; HYPEROXALURIA; IRON COMPOUNDS; RENAL DIALYSIS; TREATMENT OUTCOME; UREMIA; VITAMINS;

EID: 42949096108     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm819     Document Type: Letter

References (5)

1. Schaefer L, Schaefer RM. A primer on iron therapy. Nephrol Dial Transplant 2007; 2: 2429-2431
2. Keven K, Kutlay S, Nergizogly G et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233-1239
3. Marangella M, Vitale C, Petrarulo M et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 1995; 48: 182-187
4. Canavese C, Petrarulo M, Massarenti P et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 2005; 45: 540-549
5. Deicher R, Ziai F, Bieglmayer C et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 1811-1818